Plaque Psoriasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Plaque Psoriasis Market Outlook
Thelansis’s “Plaque Psoriasis Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Plaque Psoriasis treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Plaque
Psoriasis Overview
Psoriasis,
an immune-mediated inflammatory disease affecting skin and joints, is widely
recognized as the most prevalent and often presents abnormalities in other
bodily systems. The most common variant of psoriasis, known as plaque psoriasis
(or psoriasis vulgaris), accounts for 80-90% of all cases. It is characterized
by well-defined, erythematous, scaly plaques that frequently appear on specific
areas like the elbows, knees, scalp, and the region between the buttocks. These
plaques can vary in size, and patients may exhibit a localized condition with
only a few lesions or a more generalized manifestation. Notably, the lesions
are often symmetrically distributed, and about 80% of plaque psoriasis cases
fall into the mild to moderate category, involving less than 10% of the body
surface area. The etiology of psoriasis is multifactorial, with genetic
predisposition being a significant factor. Additionally, various triggers,
including trauma, infections, drugs, metabolic factors, stress, alcohol
consumption, smoking, and sunlight exposure, can exacerbate the condition.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment